Effect of preservative free travoprost on proximal tear drainage system using scan machine- a clinical study

Not Applicable

• Conditions: Health Condition 1: H401- Open-angle glaucoma

• Registration Number: CTRI/2023/04/051290
• Lead Sponsor: Sankara eye hospital Shimoga .

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Newly diagnosed glaucoma patients started on topical preservative free travoprost monotherapy (0.004%)

2. Patients having diameter of punctum >=0.3 mm(0.3-0.5 mm) on slit lamp biomicroscopy before starting travoprost.

3. Patients having pretreatment imaging parameters of proximal lacrimal drainage system within normal range as measured by ASOCT.

Exclusion Criteria

1. Patients diagnosed with glaucoma and started on treatment earlier.

2. History of long term ( more than 2 weeks) use of topical medications and oral medications likely to alter LDS.

3. Patient requiring adjuvant treatment to lower IOP during the study.

4 pretreatment abnormal imaging parameters of PLDS recorded by ASOCT.

5. Diseases of LDS like punctal and canalicular stenosis, atresia, agenesis, canaliculitis, nasolacrimal duct Obstruction NLDO, tumours/ lesions involving the LDS.

6. Eyelid malpositions like ectropion, entropion.

7. Cicatrising ocular diseases likely to affect LDS like Steven Johnson Syndrome, Ocular cicatricial pemphigoid, chronic conjunctivitis etc.

8. Any previous history of surgeries on LDS, eyelid.

9. History of ocular trauma involving the eyelids, LDS.

10. Previous history of ocular radiotherapy for various causes.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To study the effect of preservative free travoprost on proximal lacrimal drainage system in newly diagnosed glaucoma patients using ASOCT.Timepoint: At presentation (baseline), and on follow up visit at 3rd, 6th, 9th and 12th month.

Secondary Outcome Measures

Name	Time	Method
Measurement of external punctal diameter, internal punctal diameter and vertical canalicular depth on ASOCT..Timepoint: At presentation (baseline), and on follow up visit at 3rd, 6th, 9th and 12th month.